{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T22:10:53Z","timestamp":1794867053867,"version":"4.9.1"},"reference-count":83,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes &amp; Metabolism"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.diabet.2025.101708","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T14:27:15Z","timestamp":1760538435000},"page":"101708","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["GLP-1-derived therapies and sarcopenia: plea for a specific focus on at risk special populations"],"prefix":"10.1016","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9743-4371","authenticated-orcid":false,"given":"Andr\u00e9 J.","family":"Scheen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabet.2025.101708_bib0001","doi-asserted-by":"crossref","first-page":"206","DOI":"10.3803\/EnM.2024.1940","article-title":"Glucagon-like peptide-1 based therapies: a new horizon in obesity management","volume":"39","author":"Son","year":"2024","journal-title":"Endocrinol Metab (Seoul)"},{"key":"10.1016\/j.diabet.2025.101708_bib0002","article-title":"Why are we still in need for novel anti-obesity medications?","volume":"47","author":"Novikoff","year":"2024","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.diabet.2025.101708_bib0003","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/s41573-025-01183-8","article-title":"GLP-1-based therapies for diabetes, obesity and beyond","volume":"24","author":"Drucker","year":"2025","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.diabet.2025.101708_bib0004","first-page":"339","article-title":"Sarcopenic obesity and weight loss-induced muscle mass loss","volume":"28","author":"Caturano","year":"2025","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"10.1016\/j.diabet.2025.101708_bib0005","doi-asserted-by":"crossref","DOI":"10.1111\/1753-0407.70117","article-title":"Monitoring sarcopenia with incretin receptor activator treatment","volume":"17","author":"Bloomgarden","year":"2025","journal-title":"J Diabetes"},{"key":"10.1016\/j.diabet.2025.101708_bib0006","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S2213-8587(24)00272-9","article-title":"Muscle matters: the effects of medically induced weight loss on skeletal muscle","volume":"12","author":"Prado","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.diabet.2025.101708_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2025.101681","article-title":"GLP-1 receptor agonists, body composition, skeletal muscle and risk of sarcopenia : from promising findings in animal models to debated concern in human studies","volume":"51","author":"Scheen","year":"2025","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.diabet.2025.101708_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2025.107927","article-title":"Glucagon-like peptide-1 receptor agonists and muscle mass effects","volume":"220","author":"Ceasovschih","year":"2025","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.diabet.2025.101708_bib0009","doi-asserted-by":"crossref","DOI":"10.2337\/dbi25-0004","article-title":"Treating sarcopenic obesity in the era of incretin therapies: perspectives and challenges","author":"Chen","year":"2025","journal-title":"Diabetes"},{"key":"10.1016\/j.diabet.2025.101708_bib0010","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1161\/CIRCULATIONAHA.124.067676","article-title":"Muscle mass and glucagon-like peptide-1 receptor agonists: adaptive or maladaptive response to weight loss?","volume":"150","author":"Linge","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.diabet.2025.101708_bib0011","article-title":"The role of glucagon-like peptides in osteosarcopenia","volume":"264","author":"Tufail","year":"2025","journal-title":"J Endocrinol"},{"key":"10.1016\/j.diabet.2025.101708_bib0012","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1001\/jama.2024.6586","article-title":"Is weight loss-induced muscle mass loss clinically relevant?","volume":"332","author":"Conte","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.diabet.2025.101708_bib0013","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.clnu.2024.12.004","article-title":"Beyond fat: does semaglutide affect lean mass?","volume":"44","author":"Jamialahmadi","year":"2025","journal-title":"Clin Nutr"},{"key":"10.1016\/j.diabet.2025.101708_bib0014","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1186\/s13098-025-01877-4","article-title":"Dionysus or apollo, skeletal muscle mass changes in type 2 diabetes with sarcopenia receiving GLP-1 receptor agonist: systematic review and meta-analysis","volume":"17","author":"Wang","year":"2025","journal-title":"Diabetol Metab Syndr"},{"key":"10.1016\/j.diabet.2025.101708_bib0015","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1210\/clinem\/dgaf335","article-title":"Incretin receptor agonism, fat-free mass, and cardiorespiratory fitness: a narrative review","volume":"110","author":"Liu","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.diabet.2025.101708_bib0016","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/s41574-018-0062-9","article-title":"Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies","volume":"14","author":"Batsis","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.diabet.2025.101708_bib0017","doi-asserted-by":"crossref","first-page":"4633","DOI":"10.1016\/j.clnu.2021.06.009","article-title":"Global prevalence of sarcopenic obesity in older adults: a systematic review and meta-analysis","volume":"40","author":"Gao","year":"2021","journal-title":"Clin Nutr"},{"key":"10.1016\/j.diabet.2025.101708_bib0018","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s40266-023-01042-4","article-title":"Repurposing drugs for diabetes mellitus as potential pharmacological treatments for sarcopenia - A narrative review","volume":"40","author":"Witham","year":"2023","journal-title":"Drugs Aging"},{"key":"10.1016\/j.diabet.2025.101708_bib0019","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.2147\/DMSO.S410834","article-title":"The association between sarcopenia and diabetes: from pathophysiology mechanism to therapeutic strategy","volume":"16","author":"Chen","year":"2023","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10.1016\/j.diabet.2025.101708_bib0020","article-title":"Pathogenesis and comprehensive treatment strategies of sarcopenia in elderly patients with type 2 diabetes mellitus","volume":"14","author":"Hou","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.diabet.2025.101708_bib0021","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1002\/jcsm.13221","article-title":"Sarcopenia and cardiovascular diseases: a systematic review and meta-analysis","volume":"14","author":"Zuo","year":"2023","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.diabet.2025.101708_bib0022","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1161\/CIRCULATIONAHA.123.064071","article-title":"Sarcopenia and cardiovascular diseases","volume":"147","author":"Damluji","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.diabet.2025.101708_bib0023","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.743710","article-title":"Relationship between sarcopenia and cardiovascular diseases in the elderly: an overview","volume":"8","author":"He","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.diabet.2025.101708_bib0024","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3390\/nu12010211","article-title":"Sarcopenia and heart failure","volume":"12","author":"Curcio","year":"2020","journal-title":"Nutrients"},{"key":"10.1016\/j.diabet.2025.101708_bib0025","doi-asserted-by":"crossref","first-page":"6549","DOI":"10.3390\/ijms21186549","article-title":"Muscle wasting and sarcopenia in heart failure-the current state of science","volume":"21","author":"Lena","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.diabet.2025.101708_bib0026","doi-asserted-by":"crossref","first-page":"4019","DOI":"10.7150\/thno.33000","article-title":"New insights into the pathogenesis and treatment of sarcopenia in chronic heart failure","volume":"9","author":"Yin","year":"2019","journal-title":"Theranostics"},{"key":"10.1016\/j.diabet.2025.101708_bib0027","doi-asserted-by":"crossref","first-page":"7","DOI":"10.20517\/jca.2023.40","article-title":"Molecular mechanisms underlying sarcopenia in heart failure","volume":"4","author":"Rutledge","year":"2024","journal-title":"J Cardiovasc Aging"},{"key":"10.1016\/j.diabet.2025.101708_bib0028","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.cardfail.2019.03.007","article-title":"Nutrition, obesity, and cachexia in patients wth heart failure: a consensus statement from the Heart Failure Society of America Scientific Statements Committee","volume":"25","author":"Vest","year":"2019","journal-title":"J Card Fail"},{"key":"10.1016\/j.diabet.2025.101708_bib0029","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1002\/jcsm.13425","article-title":"Prevalence of sarcopenia in patients with chronic kidney disease: a global systematic review and meta-analysis","volume":"15","author":"Duarte","year":"2024","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.diabet.2025.101708_bib0030","doi-asserted-by":"crossref","first-page":"352","DOI":"10.3390\/biomedicines13020352","article-title":"Sarcopenia in chronic kidney disease: a narrative review from pathophysiology to therapeutic approaches","volume":"13","author":"Tsai","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.diabet.2025.101708_bib0031","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1007\/s12072-019-09996-7","article-title":"Sarcopenia and fatty liver disease","volume":"13","author":"Kim","year":"2019","journal-title":"Hepatol Int"},{"key":"10.1016\/j.diabet.2025.101708_bib0032","first-page":"1213","article-title":"Sarcopenia in chronic liver disease: a metabolic perspective","volume":"10","author":"Kumar","year":"2022","journal-title":"J Clin Transl Hepatol"},{"key":"10.1016\/j.diabet.2025.101708_bib0033","article-title":"Epidemiology of sarcopenia: prevalence, risk factors, and consequences","volume":"144","author":"Yuan","year":"2023","journal-title":"Metabolism"},{"key":"10.1016\/j.diabet.2025.101708_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2025.108824","article-title":"GLP-1 receptor agonists, are we witnessing the emergence of a paradigm shift for neuro-cardio-metabolic disorders?","volume":"269","author":"Arredouani","year":"2025","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.diabet.2025.101708_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol Metab"},{"key":"10.1016\/j.diabet.2025.101708_bib0036","article-title":"Glucagon-like peptide-1 receptor agonists: new strategies and therapeutic targets to treat atherosclerotic cardiovascular disease","volume":"15","author":"Wang","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.diabet.2025.101708_bib0037","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.cardfail.2025.01.022","article-title":"Efficacy of GLP-1 receptor agonists in patients with heart failure and mildly reduced or preserved ejection fraction: a systematic review and meta-analysis","volume":"31","author":"Waqas","year":"2025","journal-title":"J Card Fail"},{"key":"10.1016\/j.diabet.2025.101708_bib0038","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/ckj\/sfae296","article-title":"GLP-1 receptor agonists in patients with chronic kidney disease and either overweight or obesity","volume":"17","author":"Abasheva","year":"2024","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.diabet.2025.101708_bib0039","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1210\/clinem\/dgaf336","article-title":"Efficacy of GLP-1-based therapies on metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis: a systematic review and meta-analysis","volume":"110","author":"Wang","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.diabet.2025.101708_bib0040","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/j.cgh.2024.01.032","article-title":"The emerging role of glucagon-like peptide-1 receptor agonists for the treatment of metabolic dysfunction-associated steatohepatitis","volume":"22","author":"Abushamat","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.diabet.2025.101708_bib0041","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s13668-025-00649-w","article-title":"Impact of GLP- 1 receptor agonist therapy in patients high risk for sarcopenia","volume":"14","author":"Memel","year":"2025","journal-title":"Curr Nutr Rep"},{"key":"10.1016\/j.diabet.2025.101708_bib0042","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1080\/17512433.2025.2527092","article-title":"Progress towards a personalized management of antidiabetic medications in the elderly with type 2 diabetes","volume":"18","author":"Scheen","year":"2025","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.diabet.2025.101708_bib0043","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s40266-024-01150-9","article-title":"Pharmacological treatment of obesity in older adults","volume":"41","author":"Zizka","year":"2024","journal-title":"Drugs Aging"},{"key":"10.1016\/j.diabet.2025.101708_bib0044","doi-asserted-by":"crossref","first-page":"468","DOI":"10.14336\/AD.2021.0928","article-title":"Novel insights into the roles and mechanisms of GLP-1 receptor agonists against aging-related diseases","volume":"13","author":"Peng","year":"2022","journal-title":"Aging Dis"},{"key":"10.1016\/j.diabet.2025.101708_bib0045","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1080\/14656566.2021.1912735","article-title":"Careful use to minimize adverse events of oral antidiabetic medications in the elderly","volume":"22","author":"Scheen","year":"2021","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.diabet.2025.101708_bib0046","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.7326\/ANNALS-24-03950","article-title":"Skeletal muscle mass loss and glucagon-like peptide-1 receptor agonists: are older patients at risk?","volume":"178","author":"Kakkar","year":"2025","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.diabet.2025.101708_bib0047","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1111\/jgs.18816","article-title":"Should the incretin hype be the same for older adults: promise + cautions","volume":"72","author":"Batsis","year":"2024","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.diabet.2025.101708_bib0048","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/s12944-025-02622-6","article-title":"Targeting intramyocellular lipids to improve aging muscle function","volume":"24","author":"Russ","year":"2025","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.diabet.2025.101708_bib0049","doi-asserted-by":"crossref","DOI":"10.1016\/j.jnha.2025.100652","article-title":"Weighing the risk of GLP-1 treatment in older adults: should we be concerned about sarcopenic obesity?","volume":"29","author":"Prokopidis","year":"2025","journal-title":"J Nutr Health Aging"},{"key":"10.1016\/j.diabet.2025.101708_bib0050","doi-asserted-by":"crossref","first-page":"408","DOI":"10.3390\/biom15030408","article-title":"Weight reduction with GLP-1 agonists and paths for discontinuation while maintaining weight loss","volume":"15","author":"Reiss","year":"2025","journal-title":"Biomolecules"},{"key":"10.1016\/j.diabet.2025.101708_bib0051","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13929","article-title":"Discontinuing glucagon-like peptide-1 receptor agonists and body habitus: a systematic review and meta-analysis","volume":"26","author":"Berg","year":"2025","journal-title":"Obes Rev"},{"key":"10.1016\/j.diabet.2025.101708_bib0052","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1002\/oby.22493","article-title":"Weight cycling as a risk factor for low muscle mass and strength in a population of males and females with obesity","volume":"27","author":"Rossi","year":"2019","journal-title":"Obesity"},{"key":"10.1016\/j.diabet.2025.101708_bib0053","doi-asserted-by":"crossref","DOI":"10.1007\/s11154-025-09963-8","article-title":"Weight cycling and its effects on muscle mass, sarcopenia and sarcopenic obesity","author":"Zamboni","year":"2025","journal-title":"Rev Endocr Metab Disord"},{"key":"10.1016\/j.diabet.2025.101708_bib0054","doi-asserted-by":"crossref","first-page":"S266","DOI":"10.2337\/dc25-S013","article-title":"Committee. 13. Older adults: standards of care in diabetes-2025","volume":"48","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2025.101708_bib0055","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1507\/endocrj.EJ23-0384","article-title":"Efficacy and safety of glucagon-like peptide-1 receptor agonists in the elderly versus non-elderly patients with type 2 diabetes mellitus: insights from a systematic review","volume":"71","author":"Wang","year":"2024","journal-title":"Endocr J"},{"key":"10.1016\/j.diabet.2025.101708_bib0056","doi-asserted-by":"crossref","DOI":"10.1016\/j.archger.2025.105981","article-title":"Efficacy of GLP-1 receptor agonists among older adults: a meta-analysis of cardio-kidney outcome trials","volume":"138","author":"Waqas","year":"2025","journal-title":"Arch Gerontol Geriatr"},{"key":"10.1016\/j.diabet.2025.101708_bib0057","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103162","article-title":"Comparative cardiovascular effectiveness of newer glucose-lowering drugs in elderly with type 2 diabetes: a target trial emulation cohort study","volume":"82","author":"Kosjerina","year":"2025","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.diabet.2025.101708_bib0058","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S2213-8587(24)00271-7","article-title":"Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials","volume":"13","author":"Badve","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.diabet.2025.101708_bib0059","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2024.100679","article-title":"Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: a meta-analysis of randomized placebo-controlled trials","volume":"18","author":"Rivera","year":"2024","journal-title":"Am J Prev Cardiol"},{"key":"10.1016\/j.diabet.2025.101708_bib0060","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13916","article-title":"How do glucagon-like peptide-1 receptor agonists affect measures of muscle mass in individuals with, and without, type 2 diabetes: a systematic review and meta-analysis","volume":"26","author":"Anyiam","year":"2025","journal-title":"Obes Rev"},{"key":"10.1016\/j.diabet.2025.101708_bib0061","doi-asserted-by":"crossref","first-page":"5645","DOI":"10.2147\/DDDT.S531778","article-title":"Semaglutide therapy and accelerated sarcopenia in older adults with type 2 diabetes: a 24-month retrospective cohort study","volume":"19","author":"Ren","year":"2025","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.diabet.2025.101708_bib0062","article-title":"Semaglutide use is associated with neuromuscular junction degradation in older adults with type II diabetes mellitus","author":"Qaisar","year":"2025","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.diabet.2025.101708_bib0063","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3390\/nu16010063","article-title":"Sarcopenia and diabetes: a detrimental liaison of advancing age","volume":"16","author":"Lisco","year":"2023","journal-title":"Nutrients"},{"key":"10.1016\/j.diabet.2025.101708_bib0064","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(24)01643-X","article-title":"Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials","volume":"404","author":"Kosiborod","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.diabet.2025.101708_bib0065","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2024.1293537","article-title":"Is sarcopenia an associated factor of increased administration of specific medications in patients with heart failure? A systematic review and meta-analysis","volume":"11","author":"Saied","year":"2024","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.diabet.2025.101708_bib0066","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1161\/CIRCULATIONAHA.120.045888","article-title":"Glucagon-like peptide 1 receptor agonists and heart failure: the need for further evidence generation and practice guidelines optimization","volume":"142","author":"Khan","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.diabet.2025.101708_bib0067","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.cardfail.2024.01.005","article-title":"Malnutrition and sarcopenia as reasons for caution with GLP-1 receptor agonist use in HFpEF","volume":"30","author":"Driggin","year":"2024","journal-title":"J Card Fail"},{"key":"10.1016\/j.diabet.2025.101708_bib0068","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.3390\/biomedicines13051108","article-title":"Navigating sarcopenia risks in GLP-1RA therapy for advanced heart failure","volume":"13","author":"Wang","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.diabet.2025.101708_bib0069","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.2337\/dci23-0030","article-title":"Diabetic nephropathy: update on pillars of therapy slowing progression","volume":"46","author":"Naaman","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2025.101708_bib0070","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2025.101708_bib0071","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1053\/j.ajkd.2024.11.013","article-title":"Kidney and cardiovascular outcomes among patients with CKD receiving GLP-1 receptor agonists: a systematic review and meta-analysis of randomized trials","volume":"85","author":"Chen","year":"2025","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.diabet.2025.101708_bib0072","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1186\/s12964-024-01922-1","article-title":"The gut microbiome, chronic kidney disease, and sarcopenia","volume":"22","author":"Zheng","year":"2024","journal-title":"Cell Commun Signal"},{"key":"10.1016\/j.diabet.2025.101708_bib0073","article-title":"Rebalancing the gut: glucagon-like peptide-1 agonists as a strategy for obesity and metabolic health","volume":"16","author":"Singh","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.diabet.2025.101708_bib0074","doi-asserted-by":"crossref","first-page":"8096","DOI":"10.3390\/ijms26168096","article-title":"Targeting sarcopenia in CKD: the emerging role of GLP-1 receptor agonists","volume":"26","author":"Llinares-Arvelo","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.diabet.2025.101708_bib0075","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s12986-025-01000-4","article-title":"Prevalence and risk of metabolic dysfunction-associated steatotic liver disease in patients with sarcopenic obesity: a systematic review and meta-analysis","volume":"22","author":"Wang","year":"2025","journal-title":"Nutr Metab (Lond)"},{"key":"10.1016\/j.diabet.2025.101708_bib0076","doi-asserted-by":"crossref","DOI":"10.3748\/wjg.v31.i20.105346","article-title":"Metabolic dysfunction-associated steatotic liver disease: a story of muscle and mass","volume":"31","author":"Isakov","year":"2025","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.diabet.2025.101708_bib0077","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000038444","article-title":"Favorable liver and skeletal muscle changes in patients with MASLD and T2DM receiving glucagon-like peptide-1 receptor agonist: a prospective cohort study","volume":"103","author":"Kakegawa","year":"2024","journal-title":"Medicine"},{"key":"10.1016\/j.diabet.2025.101708_bib0078","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2025.102253","article-title":"Are we giving too much weight to lean mass loss?","volume":"101","author":"Bolte","year":"2025","journal-title":"Mol Metab"},{"key":"10.1016\/j.diabet.2025.101708_bib0079","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2025.112924","article-title":"GLP-1 receptor agonists and sarcopenia: weight loss at a cost? A brief narrative review","author":"Pantazopoulos","year":"2025","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.diabet.2025.101708_bib0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.archger.2024.105656","article-title":"Worldwide burden of antidiabetic drug-induced sarcopenia: an international pharmacovigilance study","volume":"129","author":"Kong","year":"2025","journal-title":"Arch Gerontol Geriatr"},{"key":"10.1016\/j.diabet.2025.101708_bib0081","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/s41366-024-01533-3","article-title":"The effect of obesity pharmacotherapy on body composition, including muscle mass","volume":"49","author":"Argyrakopoulou","year":"2025","journal-title":"Int J Obes (Lond)"},{"key":"10.1016\/j.diabet.2025.101708_bib0082","doi-asserted-by":"crossref","DOI":"10.23876\/j.krcp.24.207","article-title":"Sarcopenia, sarcopenic obesity, and frailty in individuals with chronic kidney disease: a comprehensive review","author":"Chao","year":"2025","journal-title":"Kidney Res Clin Pract"},{"key":"10.1016\/j.diabet.2025.101708_bib0083","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-078933","article-title":"Association between non-alcoholic fatty liver disease and risk of sarcopenia: a systematic review and meta-analysis","volume":"14","author":"Deng","year":"2024","journal-title":"BMJ open"}],"container-title":["Diabetes &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1262363625001028?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1262363625001028?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:05:08Z","timestamp":1769040308000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1262363625001028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":83,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1262363625001028"],"URL":"https:\/\/doi.org\/10.1016\/j.diabet.2025.101708","relation":{},"ISSN":["1262-3636"],"issn-type":[{"value":"1262-3636","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"GLP-1-derived therapies and sarcopenia: plea for a specific focus on at risk special populations","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabet.2025.101708","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101708"}}